Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $269000.0.

  • Orchestra BioMed Holdings' Gains from Investment Securities fell 6020.71% to $269000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 14375.94%. This contributed to the annual value of $1.2 million for FY2024, which is 30884.35% up from last year.
  • Orchestra BioMed Holdings' Gains from Investment Securities amounted to $269000.0 in Q3 2025, which was down 6020.71% from $428000.0 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Gains from Investment Securities ranged from a high of $1.0 million in Q2 2022 and a low of -$36000.0 during Q3 2022
  • Over the past 4 years, Orchestra BioMed Holdings' median Gains from Investment Securities value was $294000.0 (recorded in 2023), while the average stood at $357272.7.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Gains from Investment Securities plummeted by 10374.15% in 2024 and then soared by 361818.18% in 2025.
  • Orchestra BioMed Holdings' Gains from Investment Securities (Quarter) stood at $226000.0 in 2022, then skyrocketed by 30.09% to $294000.0 in 2023, then surged by 82.65% to $537000.0 in 2024, then plummeted by 49.91% to $269000.0 in 2025.
  • Its last three reported values are $269000.0 in Q3 2025, $428000.0 for Q2 2025, and $387000.0 during Q1 2025.